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Synopsis 44 
Background: Combination antiretroviral therapy (cART)-related toxicities and costs have 45 
prompted the need for treatment simplification. ATLAS-M trial explored 48-week non-46 
inferior efficacy of simplification to atazanavir/ritonavir plus lamivudine versus maintaining 47 
three-drugs atazanavir/ritonavir-based cART in virologically-suppressed patients. 48 
Methods: We performed an open-label, multicentre, randomized, non-inferiority study, 49 
enrolling HIV-infected adults on atazanavir/ritonavir plus two nucleoside reverse-50 
transcriptase inhibitors (NRTI), with stable HIV-RNA<50 copies/mL, and CD4+>200 cells/mm3. 51 
Main exclusion criteria were: HBV-coinfection, past virological failure on or resistance to 52 
study drugs, recent AIDS, and pregnancy. Patients were randomly assigned 1:1 to either 53 
switch to atazanavir 300mg/ritonavir100mg once daily and lamivudine 300mg once daily 54 
(ATV/rit+3TC arm) or to continue the previous regimen (ATV/rit+2NRTI arm). Primary study 55 
outcome was the maintenance of HIV-RNA<50copies/mL at week 48 at the intention-to-56 
treat-exposed (ITT-e) analysis with switch=failure. The non-inferiority margin was 12%. 57 
This study is registered at ClinicalTrials.gov, number NCT01599364. 58 
Results: Between July 2011 and June 2014, 266 patients were randomized (133 to each 59 
arm). After 48 weeks, the primary study outcome was met by 119/133 patients (89.5%) in 60 
the ATV/rit+3TC arm and 106/133 patients (79.7%) in the ATV/rit+2NRTI arm (difference 61 
ATV/rit+3TC versus ATV/rit+2NRTI arm: +9.8% [95% CI +1.2 to +18.4]), demonstrating non-62 
inferiority and superior efficacy of the ATV/rit+3TC arm. Virological failure occurred in two 63 
(1.5%) patients in the ATV/rit+3TC arm and six (4.5%) in the ATV/rit+2NRTI arm, without 64 
resistance selection. A similar proportion of adverse events occurred in both arms. 65 
Conclusions: Treatment simplification to atazanavir/ritonavir plus lamivudine showed non-66 
 
 
inferior efficacy (superiority on post-hoc analysis) and a comparable safety profile over 67 
continuing atazanavir/ritonavir+2NRTI in virologically-suppressed patients. 68 
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Introduction 83 
Combination antiretroviral therapy (cART) has markedly improved the prognosis of HIV-84 
infected patients,1 however, long-term exposure to antiretroviral drugs has been associated 85 
with a potential development of drug toxicity. In particular, in recent years nucleoside 86 
reverse transcriptase inhibitors (NRTI)-associated toxicities have become a matter of 87 
concern.2 Several NRTI-sparing regimens have been studied with conflicting results.3,4 Mono-88 
therapies with boosted protease inhibitors (PI/r) as simplification strategies have shown 89 
interesting results, but their efficacy is not equivalent to standard triple therapy particularly 90 
in more advanced patients.5-7  91 
Dual cART regimens including a PI/r plus lamivudine have been tested in randomized studies 92 
in treatment naïve patients8 or as simplification strategies in virologically suppressed 93 
patients.9-13 Atazanavir/ritonavir plus lamivudine showed long-term efficacy and tolerability 94 
in the single arm ATLAS pilot study11 and demonstrated non inferior efficacy when compared 95 
to atazanavir/ritonavir plus two NRTI in patient previously receiving different 3-drug 96 
combinations in the randomized SALT trial.12 The aim of our study was to explore the 97 
efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir 98 
plus lamivudine, as compared to continuing a previously stable, virologically effective 99 
regimen with atazanavir/ritonavir plus two NRTIs.  100 
 101 
 102 
 103 
 
 
Patients and methods 104 
Trial design   105 
ATLAS-M is an open-label, randomized, non-inferiority trial.  106 
 107 
Ethics  108 
The protocol was approved by the Ethics Committees of each participating centre (21 109 
hospitals in Italy) and all procedures were performed in accordance with the Declaration of 110 
Helsinki. Patients provided written informed consent to study participation before 111 
enrolment. The ATLAS-M study was registered with ClinicalTrials.gov, number NCT01599364. 112 
 113 
Participants  114 
The study enrolled adult (>18 years old), HIV-1 infected patients on an antiretroviral regimen 115 
including atazanavir/ritonavir plus two NRTI from at least three months, with HIV-RNA <50 116 
copies/mL, and CD4 >200 cells/µL from at least six months. Exclusion criteria were: previous 117 
virological failure on or resistance to atazanavir and/or lamivudine, previous exposure to 118 
mono/dual therapies, co-administration of proton pump inhibitors or other medications 119 
with known drug-drug interactions potentially reducing exposure to atazanavir, hepatitis B 120 
virus (HBV) coinfection, opportunistic infections or other AIDS-related events in the year 121 
before screening, pregnancy, lactation or planned pregnancy, major toxicities related to any 122 
of the study drugs, grade 4 laboratory abnormalities at screening (excluding blood lipids and 123 
bilirubin concentration), and any illness which could, in the clinician’s judgment, jeopardize 124 
 
 
the patient’s compliance. Patients were pre-screened to fulfil inclusion criteria on the basis 125 
of medical records, and then underwent a screening visit for confirmation. 126 
 127 
Randomization 128 
At baseline, patients were randomized 1:1 to (i) treatment switch to atazanavir 300 mg with 129 
ritonavir 100 mg once daily and lamivudine 300 mg once daily (ATV/rit+3TC arm) or (ii) to 130 
continue atazanavir 300 mg boosted with ritonavir 100 mg once daily with the same NRTI 131 
backbone (ATV/rit+2NRTI arm). Randomization was web-based, computer-assigned, and 132 
stratified according to the line of ongoing therapy (first line versus other) and the enrolling 133 
centre, using blocks of two or four elements.  134 
 135 
Procedures 136 
Follow up study visits were planned at weeks 4, 12 and every 12 weeks until week 96. At 137 
each visit, physical examination and routine laboratory tests (HIV-RNA, CD4 count, blood 138 
chemistry, urinalysis, and pregnancy test in women of reproductive age) were performed. 139 
Adherence was assessed by a previously published self-report questionnaire measuring 140 
adherence on a 0-100 visual analogue scale (VAS);14 patients reporting an adherence below 141 
90% in at least one visit were considered as sub-optimally adherent. 142 
Treatment failure (TF) was defined by any of the following: virological failure, any treatment 143 
modification or discontinuation, loss to follow-up, consent withdrawal, progression to AIDS, 144 
or death for any cause. Virological failure (VF) was defined as the first of two consecutive 145 
HIV-RNA levels >50 copies/mL or a single level above 1,000 copies/mL. Viral blips were 146 
 
 
defined as a transient HIV-RNA levels above 50 copies/mL preceded and followed by another 147 
viral load <50 copies/mL without any treatment change. 148 
In case of TF or VF, patients discontinued the study. Genotypic resistance testing was 149 
performed on plasma samples at the time of VF and interpreted according to the HIVDB 150 
version 7.0 algorithms.15 Atazanavir plasma levels were also measured in these patients 151 
using a validated technique.16 152 
Adverse events (AE) were defined as any new event of any grade occurring after baseline 153 
and were classified as drug-related or not on the basis of investigator’s judgement and 154 
scored according to the DAIDS grading scale.17 In addition, grade 3 or 4 laboratory toxicities 155 
were recorded as total events and as new events occurring after baseline. 156 
 157 
Outcomes 158 
The primary efficacy endpoint was the proportion of patients without treatment failure at 159 
week 48. Analysis of the primary efficacy endpoint was performed with both the intention-160 
to-treat-exposed (ITT-e) and the per protocol population. Moreover, a 48 week FDA-161 
snapshot analysis of treatment efficacy on the ITT-e and PP population was carried out. 162 
Secondary endpoints included the development of virological failure and drug resistance, the 163 
occurrence of clinical and laboratory AE, the changes of CD4 cell count, blood lipid levels, 164 
renal function, and self-reported adherence from baseline to week 48.  165 
 166 
Statistical analysis  167 
 
 
This study was designed as a non-inferiority trial to verify if the proportion of patients 168 
without treatment failure in the ATV/rit+3TC arm was not inferior to that in the 169 
ATV/rit+2NRTI arm. Non-inferiority margin was set at -12%. Assuming a proportion of 170 
success at 48 weeks in the ATV/rit+2NRTI arm of 90%, an α value of 5%, and a power of 80%, 171 
we calculated a required sample size of 120 patients per arm. Considering a 10% margin for 172 
patients lost to follow-up, the sample size was set at 133 patients per arm.  173 
All patients randomized at baseline, who received at least one dose of the study drugs were 174 
included in the ITT-e population. The PP population included all subjects from the ITT-e 175 
population except those with major protocol violations.  176 
Categorical variables were compared using the χ2 test or Fisher’s exact test, as appropriate. 177 
Continuous variables were compared using Student t-test or Mann-Whitney U-test as 178 
appropriate. All statistical tests were 2-tailed, and only P values of <0.05 were considered to 179 
be significant. All analyses were performed using the SPSS version 18.0 software package 180 
(SPSS Inc., Chicago, IL, USA). 181 
 182 
 183 
Results 184 
Patients’ characteristics 185 
Between July 2011 and June 2014, a total of 275 patients were screened for study 186 
participation and 266 patients were randomized, 133 subjects to each study arm (see figure 187 
 
 
1). Baseline patients demographic, clinical, virological, and immunological characteristics 188 
were similar between arms (see table 1).  189 
 190 
Treatment failures and virological failures 191 
At 48 weeks, at the ITT-e analysis patients free of TF were 119 of 133 (89.5%; 95% CI 84.3 to 192 
94.7) in the ATV/rit+3TC arm and 106 of 133 (79.7%; 95% CI 72.9 to 86.5) in the 193 
ATV/rit+2NRTI arm (difference ATV/rit+3TC minus ATV/rit+2NRTI  +9.8%, 95% CI +1.2 to 194 
+18.4, p=0.027)(see figure 2).  195 
Similar results were observed at the PP analysis: 118 of 131 (90.1%, 95% CI 85.0 to 95.2) 196 
patients in the ATV/rit+3TC arm as compared to 103 of 129 (79.8%, 95% CI 72.9 to 86.7) 197 
patients in the ATV/rit+2NRTI arm were free of TF (difference between arms +10.3%, 95% CI 198 
+1.7 to +18.9, p=0.021). 199 
These results fulfils the pre-defined non-inferiority criteria and indicates superior efficacy of 200 
switching to ATV/rit+3TC over continuing ATV/rit+2NRTI. 201 
At the 48 weeks the snapshot analysis also showed non-inferiority of switching to 202 
ATV/rit+3TC. In the ITT-e population, 115 of 133 patients in the ATV/rit+3TC  (86.5%; 95% CI 203 
80.7 to 92.3) versus 106 of 133 in the ATV/rit+2NRTI arm (79.7%; 95% CI 72.9 to 86.5) were 204 
free of TF (difference between arms +6.8%, 95% CI -2.2 to +15.8, p=0.141). In the PP 205 
population, treatment success was achieved in 114 of 131 patients in the ATV/rit+3TC  206 
(87.0%; 95% CI 81.2 to 92.8) versus 103 of 129 in the ATV/rit+2NRTI arm (79.8%; 95% CI 72.9 207 
to 86.7)(difference between arms +7.2%, 95% CI -1.8 to +16.2, p=0.119) (see figure 2). 208 
 
 
Detailed causes of treatment failure are reported in table 2. VF occurred in two (1.5%) 209 
patients in the ATV/rit+3TC arm (including one at baseline, before treatment switch) and six 210 
(4.5%) patients in the TT arm (difference between arms -3%; 95% CI -7.1 to +1.1, p=0.282); 211 
all subjects with VF were treated with atazanavir/ritonavir plus tenofovir/emtricitabine 212 
before baseline. At VF, plasma samples from seven patients (two patients in the ATV/rit+3TC 213 
arm and five in ATV/rit+2NRTI arm) were available for genotypic resistance testing and 214 
quantification of atazanavir levels. No relevant resistance mutations were detected neither 215 
in the protease nor in the reverse transcriptase gene. Undetectable atazanavir levels (<0.05 216 
mg/L) were found in one of two (50%) and three of five (60%) plasma samples obtained at 217 
the time of VF in the ATV/rit+3TC and ATV/rit+2NRTI arm, respectively; in the remaining 218 
patients, atazanavir concentration was above the suggested mid-dosing interval or trough 219 
concentration efficacy cut-off.18,19 Viral blips not leading to VF or treatment discontinuation 220 
were observed in ten (7.5%) patients in the ATV/rit+3TC arm and 16 (12.0%) in the 221 
comparator arm (p=0.302). TF due to adverse events (both potentially treatment-related 222 
and not treatment-related) did not differ between the two arms (see table 2). 223 
Since withdrawal of consent was particularly represented in the triple therapy arm and this 224 
could have been influenced by the open label design of the study, thus influencing the 225 
results, we performed an efficacy sensitivity analysis in the ITT-e population excluding 226 
patients with TF due to withdrawal of consent. In this analysis, patients free of TF were 115 227 
of 127 (90.6%; 95% CI 85.5 to 95.7) in the ATV/rit+3TC arm and 104 of 124 (83.9%; 95% CI 228 
77.4 to 90.4) in the ATV/rit+2NRTI arm (difference ATV/rit+3TC minus ATV/rit+2NRTI  +6.7%, 229 
95% CI -1.5 to +14.9, p=0.113), confirming non inferiority of dual therapy. 230 
 231 
 
 
Clinical and laboratory adverse events 232 
Overall, 68 and 90 clinical AE of any grade occurred in the ATV/rit+3TC and comparator arm, 233 
respectively. The majority of clinical AE were mild to moderate. There were seven grade 3-4 234 
clinical AE (three in the ATV/rit+3TC and four in the ATV/rit+2NRTI  arm), none of which was 235 
considered treatment-related. Overall, five renal colics occurred: three in the ATV/rit+2NRTI 236 
and two in the ATV/rit+3TC arm. Four patients demonstrated osteopenia/osteoporosis in 237 
ATV/rit+2NRTI arm (all considered related to treatment with tenofovir, leading to regimen 238 
discontinuation in 2 patients), while no bone events were observed in the dual therapy arm. 239 
No significant differences were observed between study arms in the proportion of patients 240 
with at least one clinical AE. Details about clinical AE are summarized in table 3. 241 
The proportion of patients with grade 3-4 laboratory toxicities is shown in table 4. Most 242 
grade 3-4 laboratory toxicities were transient and none led to treatment discontinuation. 243 
Incident grade 3-4 hyperbilirubinemia was more frequent in the DT arm [44 of 99 (44.4%) 244 
versus 28 of 99 (28.3%) in TT, p=0.027]. Other laboratory toxicities were equally distributed 245 
between the two arms. 246 
 247 
Evolution of CD4 cells count, lipid levels and renal function 248 
The evolution of CD4 cells counts, estimated glomerular filtration rate (eGFR), and blood 249 
lipids is illustrated in figure 3a-c.  250 
At 48 weeks, the changes from baseline CD4 cells were not significantly different between 251 
ATV/rit+3TC and comparator arm. 252 
 
 
The evolution of eGFR was more favorable in the ATV/rit+3TC as compared to the control 253 
arm: at week 48, mean change from baseline eGFR (using CKD-EPI) was +2 mL/min/1.73m2 254 
(95% CI -1 to 6) in ATV/rit+3TC versus -5 mL/min/1.73m2 (95% CI -8 to -2) in the comparator 255 
arm (p<0.001). This benefit was confirmed in the subgroup of evaluable patients using 256 
tenofovir at baseline (92 and 90 in ATV/rit+3TC and comparator arms, respectively): +3 257 
mL/min/1.73m2 (95% CI -1 to 6) in ATV/rit+3TC versus -5 mL/min/1.73m2 (95% CI -9 to -2) in 258 
the comparator arm (p<0.001). 259 
Total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and low-density 260 
lipoprotein cholesterol (LDL) showed a significant increase in the ATV/rit+3TC as compared 261 
to the control arm (see figure 3b). No significant differences in the changes of triglycerides, 262 
TC/HDL, and HDL/LDL ratios were observed between the two arms. 263 
 264 
Adherence measures 265 
Self-reported adherence was provided by 247 (92.6%) patients (125 [94.0%] in the 266 
ATV/rit+3TC and 122 [91.7%] in the control arm). During the study, the two treatment arms 267 
did not significantly differ for adherence levels at any study visit (mean change versus 268 
baseline at 48 weeks: +2% [95% CI -3 to +6] in the ATV/rit+3TC versus -2% [95% CI -4 to +1] 269 
in the comparator arm, p=0.165). Suboptimal adherence was not significantly different in 270 
patients experiencing VF as compared to those not (71.4% [5 of 7] versus 53.5% [130 of 243], 271 
p=0.457). 272 
 273 
Discussion 274 
 
 
In ATLAS-M trial,  simplification to a dual therapy with atazanavir/ritonavir and lamivudine 275 
met non-inferiority over continuation of triple therapy  at all analyses. Moreover, a 276 
statistically superior efficacy of dual therapy was shown at the primary endpoint analysis, 277 
although this analysis was not determined a priori. This superiority resulted from the 278 
combination of several factors: a lower rate of virological failure, a lower discontinuation 279 
rate for treatment-related toxicity, and the less frequent withdrawal of consent in patients 280 
randomized to ATV/rit+3TC. All three reasons may be interpreted as signs of an overall 281 
better tolerability of this regimen over the comparator. In agreement with this, a lower 282 
number of clinical adverse events and a significant improvement of renal function were 283 
observed in the ATV/rit+3TC arm versus the comparator. These results are in line with the 284 
good efficacy and tolerability observed with ATV/rit+3TC as switch therapy in the ATLAS 285 
single arm, pilot study, which extended its observation up to 144 weeks.9,11 In a previous 286 
randomized controlled study (the SALT trial) with a similar sample size as the present one, 287 
ATV/rit+3TC showed non-inferior efficacy at 48 weeks as compared with ATV/rit+ 2NRTIs in 288 
patients switching from different standard three-drug cART regimens.12 The very similar 289 
efficacy results of the SALT and ATLAS-M trial confirm the robustness of this strategy in 290 
different contexts. Superiority of ATV/rit+3TC was not shown in the SALT study, although the 291 
direction of the difference was similar to ATLAS-M, possibly because of the different design 292 
of SALT, which enrolled patients on any cART type and allowed switching of the NRTI type at 293 
baseline in those with tolerability issues. ATLAS-M did not specifically screen patients with 294 
NRTI-related toxicities but more than 80% of patients randomized to continuing their 295 
ongoing regimen were on tenofovir disoproxil fumarate. Therefore, patients in the 296 
comparator arm of ATLAS-M were exposed to a higher risk of NRTI toxicity as those in SALT, 297 
which could at least in part explain the different results.  298 
 
 
Virological failure was rare and no resistance was detected in cases that could be genotyped, 299 
confirming that the Met184Val resistance mutation to lamivudine, the drug with the lowest 300 
genetic barrier in this regimen, emerges very rarely with this regimen.9,11,12  301 
Self-reported adherence measures did not change significantly over time in both study arms 302 
but in most cases of virological failure, plasma atazanavir levels were undetectable, 303 
suggesting a relevant role of insufficient adherence in these cases.  304 
Renal function, as measured by the change of the eGFR from baseline at 48 weeks, showed a 305 
significantly better performance with ATV/rit+3TC as compared to ATV/rit+2NRTIs. The 306 
difference was slightly more prominent in the subset of patients discontinuing tenofovir. 307 
Given the renal toxicity associated with both tenofovir and atazanavir,20 we suggest that an 308 
improvement in eGFR may be particularly notable in patients interrupting tenofovir after 309 
using the two drugs combined. Unfortunately, ATLAS-M did not collect markers of tubular 310 
proteinuria, which could have allowed to analyze the effect on more specific tenofovir-311 
related renal toxicity parameters.  312 
As in several other studies contemplating the discontinuation of tenofovir disoproxil 313 
fumarate,9,12,21,22 we demonstrated an increase of total cholesterol and LDL cholesterol in 314 
the ATV/rit+3TC arm. This change has been previously described as a statin-like effect of 315 
tenofovir disoproxil fumarate.23 However, due to the concomitant increase of HDL 316 
cholesterol, the total/HDL cholesterol and the HDL/LDL cholesterol ratios remained 317 
unchanged. Therefore, the effect of these changes on the cardiovascular risk is probably 318 
neutral. 319 
Overall, results of this study significantly strengthen the evidence of the efficacy of cART 320 
strategies based on the combination of a PI/rit with lamivudine. Randomized studies have 321 
 
 
shown non-inferior efficacy of lopinavir/ritonavir with lamivudine in previously untreated 322 
and in virologically suppressed patients.8,13 However, lopinavir is associated with significant 323 
toxicities and comparator arms in these studies do not represent the state of the art of 324 
antiretroviral therapy any more. Darunavir/ritonavir with lamivudine has shown interesting 325 
results but only in small, observational studies.10,24  Other dual therapies have shown less 326 
encouraging results both in naïve and in virologically suppressed patients.3,4,25,26 Therefore, 327 
at the moment, simplification to atazanavir/ritonavir with lamivudine shows the most robust 328 
data among the two-drug regimens.  329 
In our opinion, the main strength of ATLAS-M lies on its design. Indeed, the study allowed 330 
the inclusion of patients who were already on a stable atazanavir/ritonavir based triple-331 
therapy only and prescribed the continuation of the same NRTI in the comparator arm. 332 
Therefore, the results in terms of efficacy and safety were less likely to be affected by 333 
toxicities related to the changes of other components of the regimen. 334 
The open-label design of the study represents a limitation, since it may have introduced 335 
certain biases, including a higher propensity of discontinuation due to toxicity in the triple 336 
therapy arm, which may have affected the main outcome. However, we believe that absence 337 
of major toxicity at baseline and the use of an identical pill burden in both study arms should 338 
have minimized this effect.  339 
The reduced cost of this dual regimen, thanks to both the discontinuation of an NRTI 340 
(tenofovir or abacavir in the majority of patients) and to the availability of generic  341 
lamivudine, represents an additional benefit. Moreover, the patent of atazanavir is close to 342 
expiration and this could additionally reduce costs of this combination. 343 
 
 
In conclusion, the simplification to ritonavir-boosted atazanavir with lamivudine in 344 
virologically suppressed patients on ritonavir-boosted atazanavir with two NRTIs is non-345 
inferior and superior in a post-hoc analysis as compared to the continuation of the previous 346 
triple therapy at 48 weeks. A significant beneficial effect of atazanavir/ritonavir plus 347 
lamivudine in the evolution of eGFR was also observed, particularly in subjects discontinuing 348 
tenofovir disoproxil fumarate. In virologically-suppressed patients on ritonavir-boosted 349 
atazanavir with two NRTIs who are not co-infected with HBV, a switch to dual therapy with 350 
boosted atazanavir and lamivudine may be considered.  351 
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 525 
Table 1.  Baseline patients characteristics. 526 
 
Total 
population 
n=266 
ATV/rit + 3TC 
n=133 
ATV/rit + 2 NRTIs 
n=133 
Age, years* 44 (36-50) 44 (36-49) 44 (36-51) 
Male gender 212 (79.7) 112 (84.2) 100 (75.2) 
Risk factor:    
     Heterosexual 108 (40.6) 48 (36.1) 60 (45.1) 
     Homo/bisexual 116 (43.6) 64 (48.1) 52 (39.1) 
     IDU 20 (7.5) 9 (6.8) 11 (8.3) 
     Other/unknown 22 (8.3) 12 (9.0) 10 (7.5) 
HCV co-infection 28 (10.5) 14 (10.5) 14 (10.5) 
Previous AIDS events 34 (12.8) 18 (13.5) 16 (12.0) 
Years from HIV diagnosis* 4.5 (2.2-9.5) 4.2 (2.2-9.0) 5.2 (2.6-10.3) 
Years from first cART initiation* 2.7 (1.6-5.5) 2.8 (1.7-5.1) 2.7 (1.6-6.4) 
Antiretroviral treatment  line* 2 (1-3) 2 (1-3) 2 (1-3) 
Months from last regimen 
initiation* 29.1 (17.1-53.0) 28.7 (17.9-52.9) 29.2 (16.2-54.6) 
NRTI backbone:    
     TDF+FTC/3TC 217 (81.6) 105a (78.9) 112a (84.2) 
     ABC+3TC 43 (16.2) 25 (18.8) 18 (13.5) 
     Other 6 (2.3) 3b (2.3) 3c (2.3) 
Nadir CD4 count, cells/µL* 265 (132-357) 274 (118-357) 257 (144-357) 
Current CD4 count, cells/µL* 617 (481-781) 622 (472-779) 616 (486-783) 
Months from last HIV-1 RNA >50 
copies/mL* 22.0 (12.6-45.0) 23.5 (12.6-46.5) 20.8 (12.3-44.8) 
 527 
Notes: values are expressed as n (%) except for *median (interquartile range, IQR); a one 528 
patient in each arm treated with TDF+3TC, all the others with TDF+FTC; b two zidovudine + 529 
 
 
3TC, one didanosine + 3TC; c one zidovudine + 3TC, one TDF + ABC, one no NRTI backbone 530 
(treated with atazanavir/ritonavir + raltegravir, major protocol deviation). 531 
Abbreviations: ATV/rit, atazanavir/ritonavir; 3TC, lamivudine; NRTI, nucleos(t)ide reverse 532 
transcriptase inhibitors; HCV, hepatitis C virus; cART, combination Antiretroviral Therapy; 533 
TDF, tenofovir; FTC, emtricitabine; ABC, abacavir. 534 
535 
 
 
 536 
Table 2: Causes of treatment failure. 537 
 538 
 539 
 
ATV/rit + 3TC 
N=133 
ATV/rit + 2 NRTIs 
N=133 p 
Any cause 14 (10.2) 27 (20.3) 0.042 
Virological Failure 2 (1.5) 6 (4.5) 0.282 
Adverse events 
(potentially treatment-related)a 2 (1.5) 5 (3.8) 0.447 
Adverse events 
(not treatment related)b 2 (1.5) 3 (2.3) 1.000 
Withdrawal of consent 2 (1.5) 7 (5.3) 0.172 
Loss to follow-up 5 (3.8) 4 (3.0) 1.000 
Other 1 (0.8) 2 (1.5) 0.624 
 540 
Abbreviations: ATV/rit, atazanavir/ritonavir; 3TC, lamivudine; NRTI, nucleos(t)ide reverse 541 
transcriptase inhibitors. 542 
Notes:  543 
a ATV/rit + 3TC arm: skin rash (week 4) and renal colic (week 26); ATV/rit + 2NRTI arm: 544 
creatinine increase (week 3 and week 7), osteopenia (week 16), renal colic (week 24), drug 545 
nephropathy (week 43). 546 
b ATV/rit + 3TC arm: death (week 10, sudden death, probably cardiac), thyroid carcinoma 547 
(week 24); ATV/rit + 2NRTI arm: spinal disc herniation (week 3), pneumonia (week 12), 548 
abdominal cancer (week 48).  549 
 550 
 551 
552 
 
 
 553 
Table 3: Proportion of patients with any grade clinical adverse events. 554 
 ATV/rit + 3TC 
n=133 
ATV/rit + 2NRTI 
n=133 P 
Central Nervous System 3 (2.3) 4 (3.0) 1.000 
Gastrointestinal  6 (4.5) 9 (6.8) 0.595 
Skin and soft tissues 4 (3.0) 0 0.122 
Urinary tract 5 (3.8) 8 (6.0) 0.571 
Respiratory tract  8 (6.0) 6 (4.5) 0.784 
Infections 12 (9.0) 13 (9.8) 0.834 
Neoplasm  3 (2.3) 1 (0.8) 0.622 
Bone 0 4 (3.0) 0.122 
Other 12 (9.0) 20 (15.0) 0.187 
Patients with at least one AE 33 (24.8) 40 (30.1) 0.410 
 555 
Abbreviations: ATV/rit, atazanavir/ritonavir; 3TC, lamivudine; NRTI, nucleos(t)ide reverse 556 
transcriptase inhibitors. 557 
Note: Grade 3-4 clinical AE were 3 in the ATV/rit + 3TC arm (sudden death probably cardiac, 558 
thyroid carcinoma, atrial fibrillation) and 4 in the ATV/rit + 2NRTI arm (abdominal cancer, 559 
pneumonia, radiculitis, traumatic tibia fracture and finger amputation): all were not 560 
considered treatment-related. 561 
 562 
 563 
 564 
 565 
 
 
 566 
Table 4: Proportion of patients with grade 3-4 laboratory toxicities. 567 
 Total grade 3-4 toxicities  New* grade 3-4 toxicities 
 ATV/rit + 3TC  n 
(%) 
ATV/rit + 
2NRTI  
n (%) 
P 
 ATV/rit + 3TC   
n (%) 
ATV/rit + 
2NRTI  
n (%) 
P 
Total cholesterol 7/133 (5.3) 3/133 (2.3) 0.334  6/126 (4.8) 1/126 (0.8) 0.120 
LDL cholesterol 17/133 (12.8) 8/133 (6.0) 0.093  10/111 (9.0) 5/115 (4.3) 0.188 
Triglycerides 8/133 (6.0) 2/133 (1.5) 0.103  8/126 (6.3) 2/128 (1.6) 0.059 
Total bilirubin 71/133 (53.4) 58/133 (43.6) 0.141  44/99 (44.4) 28/99 (28.3) 0.027 
ALT 0/133 (0) 1/133 (0.8) 1.000  0/133 (0) 0/133 (0) Nc 
At least one laboratory 
toxicity 
92/133 (69.2) 87/133 (65.4) 0.601 
 
64/133 (48.1) 49/133 (36.8) 0.082 
 568 
Abbreviations: Nc, not computable. 569 
Notes: * incident toxicity, not present at baseline. 570 
 571 
 572 
 573 
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 577 
Figure legends 578 
 579 
Figure 1. Flow chart showing patient allocation throughout the study and main study 580 
outcomes. ATV/rit = atazanavir/ritonavir; 3TC = lamivudine; NRTI = nucleos(t)ide reverse 581 
transcriptase inhibitors); TDF/FTC, tenofovir/emtricitabine; RAL, raltegravir; ITT-e = intent-582 
to-treat-exposed; PP = per protocol. 583 
Note: * All randomized patients received at least one dose of study drugs and were thus 584 
included in the safety analysis exploring clinical and laboratory adverse events. 585 
 586 
Figure 2. Lower part: proportion of patients without treatment failure at week 48 in the two 587 
study arms in the main analysis and the FDA snapshot analysis both in the ITT-e (intent-to-588 
treat-exposed) and PP (per protocol) populations. Upper part: the main analysis shows 589 
superiority of the atazanavir/ritonavir + lamivudine arm (ATV/rit+3TC) over the 590 
atazanavir/ritonavir + 2 nucleoside analogues (ATV/rit+2NRTI) arm in both the ITT-e and the 591 
PP population. The FDA snapshot analysis shows non-inferiority of ATV/rit+3TC in both the 592 
ITT-e and PP population. 593 
 594 
Figure 3. Mean change from baseline values at week 48 in the atazanavir/ritonavir + 595 
lamivudine arm (ATV/rit+3TC) and the atazanavir/ritonavir + 2 nucleoside analogues 596 
(ATV/rit+2NRTI) arm for (a) peripheral blood CD4+ T cell counts, (b) blood lipids and (c) 597 
 
 
estimated glomerular filtration rate (eGFR) based on the MDRD and the CKD-EPI equations. 598 
TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein 599 
cholesterol; TG, triglycerides. 600 
 601 
